Letter: combination of biologics in inflammatory bowel diseases. Authors' reply
Aliment Pharmacol Ther
.
2020 Aug;52(3):568-569.
doi: 10.1111/apt.15919.
Authors
Edward Yang
1
,
Nicola Panaccione
2
,
Natalie Whitmire
1
,
Parambir S Dulai
1
,
Niels Vande Casteele
1
,
Siddharth Singh
1
,
Brigid S Boland
1
,
Angelina Collins
1
,
William J Sandborn
1
,
Remo Panaccione
3
,
Robert Battat
1
4
Affiliations
1
Division of Gastroenterology, Department of Medicine, UCSD Inflammatory Bowel Disease Center, La Jolla, CA, USA.
2
Faculty of Health Science, Western University, London, ON, Canada.
3
Division of Gastroenterology, Department of Medicine, University of Calgary Inflammatory Bowel Disease Center, Calgary, AB, Canada.
4
Division of Gastroenterology and Hepatology, Weill Cornell Medicine, Jill Roberts Center for Inflammatory Bowel Disease, New York, NY, USA.
PMID:
32656846
DOI:
10.1111/apt.15919
No abstract available
Publication types
Letter
Comment
MeSH terms
Biological Products*
Crohn Disease*
Humans
Inflammatory Bowel Diseases*
Substances
Biological Products
Grants and funding
K23 DK117058/DK/NIDDK NIH HHS/United States